Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Change in Receivables for 10 consecutive years, with -$1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 369.44% to -$1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $951000.0, a 103.4% increase, with the full-year FY2025 number at $951000.0, up 103.4% from a year prior.
  • Change in Receivables was -$1.6 million for Q4 2025 at Intellia Therapeutics, down from -$303000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $30.0 million in Q4 2023 to a low of -$24.1 million in Q2 2024.
  • A 5-year average of $366900.0 and a median of $61000.0 in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: skyrocketed 11850.98% in 2023, then tumbled 16059.6% in 2024.
  • Intellia Therapeutics' Change in Receivables stood at -$460000.0 in 2021, then skyrocketed by 44.57% to -$255000.0 in 2022, then surged by 11850.98% to $30.0 million in 2023, then crashed by 101.12% to -$337000.0 in 2024, then plummeted by 369.44% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Change in Receivables are -$1.6 million (Q4 2025), -$303000.0 (Q3 2025), and $849000.0 (Q2 2025).